AR123767A1 - Inmunidad mediada por células t mediante bioingeniería, materiales y otros métodos para modular el cúmulo de diferenciación iv y/o viii - Google Patents

Inmunidad mediada por células t mediante bioingeniería, materiales y otros métodos para modular el cúmulo de diferenciación iv y/o viii

Info

Publication number
AR123767A1
AR123767A1 ARP210102816A ARP210102816A AR123767A1 AR 123767 A1 AR123767 A1 AR 123767A1 AR P210102816 A ARP210102816 A AR P210102816A AR P210102816 A ARP210102816 A AR P210102816A AR 123767 A1 AR123767 A1 AR 123767A1
Authority
AR
Argentina
Prior art keywords
expressing
cell
antibody
cells
enriching
Prior art date
Application number
ARP210102816A
Other languages
English (en)
Inventor
Rajkumar Ganesan
Sanjaya Singh
Iqbal S Grewal
Michael Riis Hansen
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of AR123767A1 publication Critical patent/AR123767A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

En la presente descripción, en ciertos aspectos, se proporcionan anticuerpos que se unen a CD8, así como células recombinantes que contienen los vectores y composiciones que comprenden los anticuerpos. También se proporcionan en la presente descripción, en ciertos aspectos, anticuerpos que se unen a CD4, así como células recombinantes que contienen los vectores, y composiciones que comprenden los anticuerpos. También se proporcionan en la presente descripción, en ciertos aspectos, anticuerpos multiespecíficos que se unen a CD4 y CD8, así como a células recombinantes que contienen los vectores, y composiciones que comprenden los anticuerpos. También se proporcionan métodos para elaborar los anticuerpos. Reivindicación 19: Un ácido nucleico que codifica el anticuerpo de una cualquiera de las reivindicaciones 1 a 18. Reivindicación 20: Un vector que comprende el ácido nucleico de la reivindicación 19. Reivindicación 21: Una célula huésped que comprende el vector de la reivindicación 20. Reivindicación 24: Una composición farmacéutica que comprende el anticuerpo de una cualquiera de las reivindicaciones 1 a 18, y un portador farmacéuticamente aceptable. Reivindicación 25: Un método para producir la composición farmacéutica de la reivindicación 24, que comprende combinar el anticuerpo con un portador farmacéuticamente aceptable para obtener la composición farmacéutica. Reivindicación 26: Un método para activar una célula T, que comprende poner en contacto la célula T con el anticuerpo de una cualquiera de las reivindicaciones 1 a 18. Reivindicación 27: Un método para enriquecer, aislar, separar, purificar, clasificar, seleccionar, capturar o detectar una célula, en donde (A) la célula es una célula que expresa CD8, en donde el método comprende: (i) proporcionar una muestra que comprende la célula que expresa CD8; poner en contacto la muestra con el anticuerpo CD8 de una cualquiera de las reivindicaciones 1 a 18; y enriquecer, aislar, separar, purificar, clasificar, seleccionar, capturar o detectar la célula que expresa CD8 unida al anticuerpo CD8, (ii) poner en contacto una célula que expresa CD8 con el anticuerpo CD8 de una cualquiera de las reivindicaciones 1 a 18; y enriquecer, aislar, separar, purificar, clasificar, seleccionar, capturar o detectar la célula que expresa CD8 unida al anticuerpo CD8, o (iii) poner en contacto una célula que expresa CD8 con el anticuerpo CD8 de una cualquiera de las reivindicaciones 1 a 18; y enriquecer, aislar, separar, purificar, clasificar, seleccionar, capturar o detectar la célula que expresa CD8 basado en la unión de la célula que expresa CD8 al anticuerpo CD8, en donde opcionalmente la célula que expresa CD8 es una célula T, en donde opcionalmente la célula T es un linfocito T citotóxico de CD8+ (CTL); (B) la célula es una célula que expresa CD4, en donde el método comprende: (i) proporcionar una muestra que comprende la célula que expresa CD4; poner en contacto la muestra con el anticuerpo CD4 de una cualquiera de las reivindicaciones 1 a 18; y enriquecer, aislar, separar, purificar, clasificar, seleccionar, capturar o detectar la célula que expresa CD4 unida al anticuerpo CD4, (ii) poner en contacto una célula que expresa CD4 con el anticuerpo CD4 de una cualquiera de las reivindicaciones 1 a 18; y enriquecer, aislar, separar, purificar, clasificar, seleccionar, capturar o detectar la célula que expresa CD4 unida al anticuerpo CD4, o (iii) poner en contacto una célula que expresa CD4 con el anticuerpo CD4 de una cualquiera de las reivindicaciones 1 a 18; y enriquecer, aislar, separar, purificar, clasificar, seleccionar, capturar o detectar la célula que expresa CD4 sobre la base de la unión de la célula que expresa CD4 al anticuerpo CD4, en donde opcionalmente la célula que expresa CD4 es una célula T, en donde opcionalmente la célula T es una célula T colaboradora de CD4+; o (C) la célula es una célula que expresa CD4 y/o una célula que expresa CD8, en donde el método comprende: (i) proporcionar una muestra que comprende las células que expresan CD4 y/o células que expresan CD8; poner en contacto la muestra con el anticuerpo multiespecífico que se une a CD8 y CD4 de una cualquiera de las reivindicaciones 1 a 18; y enriquecer, aislar, separar, purificar, clasificar, seleccionar, capturar o detectar las células que expresan CD4 y/o las células que expresan CD8 unidas al anticuerpo multiespecífico, (ii) poner en contacto las células que expresan CD4 y/o las células que expresan CD8 con el anticuerpo multiespecífico que se une a CD8 y a CD4 de una cualquiera de las reivindicaciones 1 a 18; y enriquecer, aislar, separar, purificar, clasificar, seleccionar, capturar o detectar las células que expresan CD4 y/o las células que expresan CD8 unidas al anticuerpo multiespecífico, o (iii) poner en contacto las células que expresan CD4 y/o las células que expresan CD8 con el anticuerpo multiespecífico que se une a CD8 y a CD4 de una cualquiera de las reivindicaciones 1 a 18; y enriquecer, aislar, separar, purificar, clasificar, seleccionar, capturar o detectar las células que expresan CD4 y/o las células que expresan CD8 basado en la unión de las células que expresan CD4 y/o las células que expresan CD8 al anticuerpo multiespecífico, en donde opcionalmente las células que expresan CD4 y/o células que expresan CD8 son células T, en donde opcionalmente las células que expresan CD4 son células T colaboradoras de CD4+, en donde opcionalmente las células que expresan CD8 son CTL de CD8+.
ARP210102816A 2020-10-13 2021-10-12 Inmunidad mediada por células t mediante bioingeniería, materiales y otros métodos para modular el cúmulo de diferenciación iv y/o viii AR123767A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063091078P 2020-10-13 2020-10-13

Publications (1)

Publication Number Publication Date
AR123767A1 true AR123767A1 (es) 2023-01-11

Family

ID=81078725

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210102816A AR123767A1 (es) 2020-10-13 2021-10-12 Inmunidad mediada por células t mediante bioingeniería, materiales y otros métodos para modular el cúmulo de diferenciación iv y/o viii

Country Status (10)

Country Link
US (1) US11926667B2 (es)
EP (1) EP4228693A4 (es)
JP (1) JP2023544890A (es)
KR (1) KR20230086765A (es)
CN (1) CN116635052A (es)
AR (1) AR123767A1 (es)
CA (1) CA3198590A1 (es)
TW (1) TW202231292A (es)
UY (1) UY39467A (es)
WO (1) WO2022081516A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230086765A (ko) * 2020-10-13 2023-06-15 얀센 바이오테크 인코포레이티드 분화 클러스터 iv 및/또는 viii을 조절하기 위한 바이오-조작된 t 세포 매개 면역, 물질 및 기타 방법
KR20230112632A (ko) 2020-10-23 2023-07-27 애셔 바이오테라퓨틱스, 인크. 면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합
US12637503B2 (en) 2020-11-03 2026-05-26 K-Bio Investment, Llc Antigen-binding molecules that bind to Porphyromonas gingivalis
WO2022245500A1 (en) 2021-05-19 2022-11-24 Asher Biotherapeutics, Inc. Il-21 polypeptides and targeted constructs
EP4514843A1 (en) * 2022-04-26 2025-03-05 K-Bio Investment, LLC Formulation for antigen-binding molecules that bind to porphyromonas gingivalis
CN119546343A (zh) * 2022-04-27 2025-02-28 亚设生物治疗公司 细胞因子融合蛋白与cd8抗原结合分子的组合
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
CN117736299B (zh) * 2023-12-20 2025-12-19 杭州斯达特生物科技有限公司 重组人源CD8α蛋白及其制备方法与应用
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US6011146A (en) 1991-11-15 2000-01-04 Institut Pasteur Altered major histocompatibility complex (MHC) determinant and methods of using the determinant
US5734023A (en) 1991-11-19 1998-03-31 Anergen Inc. MHC class II β chain/peptide complexes useful in ameliorating deleterious immune responses
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5820866A (en) 1994-03-04 1998-10-13 National Jewish Center For Immunology And Respiratory Medicine Product and process for T cell regulation
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869270A (en) 1996-01-31 1999-02-09 Sunol Molecular Corporation Single chain MHC complexes and uses thereof
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
AU741130B2 (en) 1997-09-16 2001-11-22 Oregon Health Sciences University Recombinant MHC molecules useful for manipulation of antigen-specific T-cells
GB9720054D0 (en) 1997-09-19 1997-11-19 Celltech Therapeutics Ltd Biological products
US6232445B1 (en) 1997-10-29 2001-05-15 Sunol Molecular Corporation Soluble MHC complexes and methods of use thereof
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
PT1644412E (pt) 2003-07-01 2015-12-23 Ucb Biopharma Sprl Fragmentos de anticorpos fab modificados
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
WO2008020827A2 (en) 2005-08-01 2008-02-21 Biogen Idec Ma Inc. Altered polypeptides, immunoconjugates thereof, and methods related thereto
DK1999154T3 (da) 2006-03-24 2012-12-03 Merck Patent Gmbh Fremstillede heterodimere proteindomæner
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
JP2012505654A (ja) 2008-10-14 2012-03-08 ヤンセン バイオテツク，インコーポレーテツド 抗体をヒト化及び親和性成熟する方法
DK3178835T3 (da) 2009-02-03 2019-06-24 Amunix Pharmaceuticals Inc Forlængede rekombinante polypeptider og sammensætninger omfattende samme
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
KR102049223B1 (ko) * 2010-11-04 2019-11-28 베링거 인겔하임 인터내셔날 게엠베하 항－ｉｌ－２３ 항체
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
TWI736437B (zh) 2010-11-30 2021-08-11 日商中外製藥股份有限公司 細胞傷害誘導治療劑
IN2014CN03887A (es) 2011-10-27 2015-10-16 Genmab As
US9574010B2 (en) 2011-11-04 2017-02-21 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
US9527927B2 (en) 2011-12-20 2016-12-27 Medimmune, Llc Modified polypeptides for bispecific antibody scaffolds
WO2013157953A1 (en) 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
AU2013351542B2 (en) 2012-11-28 2018-08-09 BioNTech SE Individualized vaccines for cancer
MX385344B (es) 2012-11-28 2025-03-18 Zymeworks Bc Inc Pares de cadena pesada-cadena ligera de inmunoglobulina modificados genéticamente y usos de estos.
CA2906566C (en) 2013-03-14 2024-09-10 Macrogenics, Inc. Immunoreactive bispecific molecules at immune effector cells expressing an activation receptor
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
EP3587448B1 (en) 2013-03-15 2021-05-19 Xencor, Inc. Heterodimeric proteins
US10047167B2 (en) 2013-03-15 2018-08-14 Eli Lilly And Company Methods for producing fabs and bi-specific antibodies
PT2970980T (pt) 2013-03-15 2018-11-19 Janssen Biotech Inc Métodos de produção para controlor o teor de lisina c-terminal, galactose e ácido siálico em proteínas recombinantes
US10647768B2 (en) 2014-05-29 2020-05-12 Macrogenics, Inc. Multi-chain polypeptide-containing tri-specific binding molecules
US10428155B2 (en) 2014-12-22 2019-10-01 Xencor, Inc. Trispecific antibodies
JP6913032B2 (ja) 2015-05-20 2021-08-04 ザ・ブロード・インスティテュート・インコーポレイテッド 共通ネオ抗原
WO2017040324A1 (en) 2015-08-28 2017-03-09 The Trustees Of The University Of Pennsylvania Methods and compositions for cells expressing a chimeric intracellular signaling molecule
EP3150636A1 (en) 2015-10-02 2017-04-05 F. Hoffmann-La Roche AG Tetravalent multispecific antibodies
US20190031785A1 (en) 2016-01-13 2019-01-31 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
CN109071632B (zh) 2016-02-05 2022-12-30 奥里尼斯生物科学私人有限公司 靶向性治疗剂及其用途
SG11201808196UA (en) 2016-03-31 2018-10-30 Neon Therapeutics Inc Neoantigens and methods of their use
WO2017177207A1 (en) 2016-04-07 2017-10-12 Bostongene, Llc Construction and methods of use of a therapeutic cancer vaccine library comprising fusion-specific vaccines
US11534496B2 (en) 2016-06-07 2022-12-27 The Brigham And Women's Hospital, Inc. Compositions and methods relating to T peripheral helper cells in autoantibody-associated conditions
CN109843926B (zh) 2016-09-30 2023-01-20 豪夫迈·罗氏有限公司 针对cd3的双特异性抗体
WO2018170096A1 (en) * 2017-03-14 2018-09-20 Dualogics, Llc Use of a cd4/cd8 bispecific antibody for the treatment of diabetes
WO2018199318A1 (ja) * 2017-04-28 2018-11-01 国立大学法人高知大学 抗ｇｐｃ－１抗体
CN110997013B (zh) * 2017-07-24 2022-09-20 瑞泽恩制药公司 抗cd8抗体和其用途
WO2019033043A2 (en) * 2017-08-11 2019-02-14 Genentech, Inc. ANTI-CD8 ANTIBODIES AND USES THEREOF
KR20200142525A (ko) 2018-04-05 2020-12-22 노파르티스 아게 암에 대한 삼중특이성 결합 분자 및 이의 용도
TW202010757A (zh) 2018-04-11 2020-03-16 美商英伊布里克斯公司 具有經受限cd3結合的多重特異性多肽構築體以及相關方法及用途
EA202092849A1 (ru) 2018-05-24 2021-03-16 Янссен Байотек, Инк. Моноспецифические и мультиспецифические антитела к tmeff2 и их применение
WO2020060924A1 (en) * 2018-09-17 2020-03-26 Dualogics, Llc Use of a cd4/cd8 bispecific antibody for the treatment of autoimmune/inflammatory disorders
PH12022551470A1 (en) 2019-12-18 2023-05-03 Janssen Biotech Inc Materials and methods for in vivo biological targeting
KR20230086765A (ko) * 2020-10-13 2023-06-15 얀센 바이오테크 인코포레이티드 분화 클러스터 iv 및/또는 viii을 조절하기 위한 바이오-조작된 t 세포 매개 면역, 물질 및 기타 방법

Also Published As

Publication number Publication date
US11926667B2 (en) 2024-03-12
EP4228693A1 (en) 2023-08-23
CA3198590A1 (en) 2022-04-21
UY39467A (es) 2022-04-29
TW202231292A (zh) 2022-08-16
JP2023544890A (ja) 2023-10-25
KR20230086765A (ko) 2023-06-15
US20220112288A1 (en) 2022-04-14
WO2022081516A1 (en) 2022-04-21
CN116635052A (zh) 2023-08-22
EP4228693A4 (en) 2024-12-18

Similar Documents

Publication Publication Date Title
AU2023248053B2 (en) Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
Alsuliman et al. A robust, good manufacturing practice–compliant, clinical-scale procedure to generate regulatory T cells from patients with amyotrophic lateral sclerosis for adoptive cell therapy
RU2016145424A (ru) Способы выделения, культивирования и генетической инженерии популяций клеток иммунной системы для адоптивной терапии
Trzonkowski et al. Treatment of graft-versus-host disease with naturally occurring T regulatory cells
AR123935A1 (es) COMPOSICIONES Y MÉTODOS PARA MODULAR LA INMUNIDAD MEDIADA POR LA CADENA d g
WO2017178572A1 (en) Ex vivo bite-activated t cells
US10316291B2 (en) Immuno-oncology mesodermal progenitor (ioMP) cell
US10758568B2 (en) Regulatory T-cells for use in the treatment of inflammatory disorders of the human gastrointestinal tract
Archila et al. Tetramer-guided epitope mapping: a rapid approach to identify HLA-restricted T-cell epitopes from composite allergens
AR122496A1 (es) Métodos para preparar vesículas extracelulares y usos de estas
US20170038395A1 (en) Cd8+ regulatory t-cells for use in the treatment of inflammatory and autoimmune diseases
Iwaszkiewicz-Grzes et al. Antigen-reactive regulatory T cells can be expanded in vitro with monocytes and anti-CD28 and anti-CD154 antibodies
McMurchy et al. In vitro generation of human T regulatory cells: generation, culture, and analysis of FOXP3-transduced T cells
EP3509631B1 (en) In vitro propagation of babesia microti
US11124766B2 (en) Growth and survival compositions for cells capable of producing antibodies and methods related thereto
US20170368100A1 (en) Method for the identification of transiently foxp3 negative regulatory t-cells from human peripheral blood
EP4255452A1 (en) Methods of selectively targeting cd6 high cells and decreasing activity of t eef cells
Peters et al. Specific selection of stimulation-responsive γδ T-cells utilizing a short-term activation assay
Céspedes et al. Synthetic antigen-presenting cells reveal the diversity and functional specialisation of extracellular vesicles composing the fourth signal of T cell immunological synapses
Dustin A wish-list for modeling immunological synapses
CN120554482A (zh) 一种具有流感病毒血凝素蛋白特异性识别功能的γδT细胞受体及其应用
der Meijden et al. 4HLA-DPB1 mismatching results in the generation of
Golay et al. B Lymphocyte Surface Antigens Involved in the Regulation of Immunoglobulin
NZ727479B2 (en) Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy
NZ802035A (en) Methods and means for the production of ig-like molecules

Legal Events

Date Code Title Description
FB Suspension of granting procedure